Seite 1 von 8
Neuester Beitrag: 22.05.20 10:37
|Eröffnet am:||25.08.17 09:27||von: Evidencebase.||Anzahl Beiträge:||196|
|Neuester Beitrag:||22.05.20 10:37||von: Glatzenkogel||Leser gesamt:||30.237|
|Seite: < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 8 >|
Anzeichen für einen Fail in der Vergangenheit
"Genfit blamed the negative results on a higher-than-expected placebo response, although elafibranor had a history of poor study outcomes. A Phase 2 study conducted in 2015 also failed to show any improvements in NASH symptoms compared to a placebo. Instead of discontinuing the drug’s development, Genfit conducted a post-hoc analysis to find a subset of patients in the study where elafibranor showed greater activity."
Phase3 RESOLVE-IT Studie wird in 2020 für weitere Kosten sorgen
"The financial situation is potentially complicated by the debt Genfit took on in 2017. To fund the phase 3 trial and other activities, Genfit issued €180 million in convertible bonds in 2017. The bonds, which are convertible into new shares and exchangeable for existing shares, are due to be redeemed in October 2022. Converting the bonds into new shares will causeequity dilution."